Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2016-11-16 (9 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LORIENT (56100), Morbihan
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DE KERFICHANT : revenue, balance sheet and financial ratios
PHARMACIE DE KERFICHANT is a French company
founded 9 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LORIENT (56100),
this company of category PME
shows in 2023 a revenue of 2.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DE KERFICHANT (SIREN 823772348)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
N/C
2 511 161 €
N/C
N/C
N/C
N/C
N/C
Net income
169 576 €
187 075 €
126 368 €
126 047 €
202 714 €
98 061 €
121 589 €
125 622 €
EBITDA
N/C
N/C
176 932 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
5.0%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE DE KERFICHANT generates positive net income of 170 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 126 k€ -> 170 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
169 576 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 101%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 42%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
100.78%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
42.495%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DE KERFICHANT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
860.174
436.406
393.342
231.206
180.458
147.664
127.662
100.78
Financial autonomy
9.162
16.878
18.138
26.415
31.832
34.18
37.68
42.495
Repayment capacity
None
None
None
None
None
9.267
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
4.636%
None%
None%
Sector positioning
Debt ratio
100.782025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Average
In 2025, the debt ratio of PHARMACIE DE KERFICHANT (100.78) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
42.49%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Average
In 2025, the financial autonomy of PHARMACIE DE KERFICHANT (42.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
9.27 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE DE KERFICHANT (9.27) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 209.01. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
209.012
Liquidity indicators evolution PHARMACIE DE KERFICHANT
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
188.966
244.271
222.664
216.86
256.036
172.478
207.815
209.012
Interest coverage
None
None
None
None
None
5.721
None
None
Sector positioning
Liquidity ratio
209.012025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good+17 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE DE KERFICHANT (209.01) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
5.72x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of PHARMACIE DE KERFICHANT (5.7x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DE KERFICHANT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
287 076 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
31
0
0
Customer payment term (days)
0
0
0
0
0
5
0
0
Supplier payment term (days)
0
0
0
0
0
51
0
0
Positioning of PHARMACIE DE KERFICHANT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DE KERFICHANT is estimated at
2 693 734 €
(range 1 827 981€ - 4 226 841€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1827k€2693k€4226k€
2 693 734 €Range: 1 827 981€ - 4 226 841€
NAF 5 année 2025
Valuation method used
Net Income Multiple
169 576 €
×
15.9x
=2 693 735 €
Range: 1 827 981€ - 4 226 841€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DE KERFICHANT with other companies in the same sector:
Frequently asked questions about PHARMACIE DE KERFICHANT
What is the revenue of PHARMACIE DE KERFICHANT ?
The revenue of PHARMACIE DE KERFICHANT in 2023 is 2.5 M€.
Is PHARMACIE DE KERFICHANT profitable?
Yes, PHARMACIE DE KERFICHANT generated a net profit of 170 k€ in 2025.
Where is the headquarters of PHARMACIE DE KERFICHANT ?
The headquarters of PHARMACIE DE KERFICHANT is located in LORIENT (56100), in the department Morbihan.
Where to find the tax return of PHARMACIE DE KERFICHANT ?
The tax return of PHARMACIE DE KERFICHANT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DE KERFICHANT operate?
PHARMACIE DE KERFICHANT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart